SWOG clinical trial number
SWOG-9242

Evaluation of Taxotere in Small Cell Lung Carcinoma, Phase II

Closed
Phase
Accrual
94%
Published
Abbreviated Title
Evaluation of Taxotere in Small Cell Lung Carcinoma, Phase II
Activated
05/01/1993
Closed
01/15/1997

Research committees

Lung Cancer

Publication Information Expand/Collapse

1999

Evaluation of docetaxel in previously untreated extensive stage small cell lung cancer: A Southwest Oncology Group phase II trial.

PJ Hesketh;JJ Crowley;HA Burris;SK Williamson;SP Balcerzak;DM Peereboom;JW Goodwin;HM Gross;DF Moore;RB Livingston;DR Gandara Cancer Journal from Scientific American 5(4):237-241

1998

Docetaxel (taxotere) in extensive stage small cell lung cancer (SCLC): A phase II trial of the Southwest Oncology Group (SWOG).

HA Burris;JJ Crowley;SK Williamson;DR Gandara;RB Livingston Proc of the American Society of Clinical Oncology 17:451a(#1737)

Other Clinical Trials

SWOG Clinical Trial Number
A082302

EVALUATING ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS TO PREVENT RECURRENCE IN STAGE I NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III TRIAL (AASI-NSCLC)
Research Committee(s)
Lung Cancer
Activated
03/02/2027
Open
SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase